compounded semaglutide weight loss effectiveness Timeline & Biomarker Insights Semaglutide in Med Spas: Transformative

Anaphylaxis following a B12 injection has been documented in medical literature, particularly in patients with a sensitivity to cobalt or cobalamin compounds

April 22, 2026: Removed from Category 2 On April 15, 2026, the FDA published a 503A category revision removing 12 peptides from Category 2 effective seven calendar days later (April 22)

This page is a research reference for the doses studied in trials

This should give it ample runway over the next several quarters as it continues to develop aleniglipron, with the drug candidate moving toward a critical Phase 3 trial.

Continuous review helps ensure that other chronic medications remain appropriately dosed